SEARCH

SEARCH BY CITATION

References

  • Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F. M., Liu J. and Kunos G. (2005) Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106, 133145.
  • Bhat R. V., Budd Haeberlein S. L. and Avila J. (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89, 13131317.
  • Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G. and Casellas P. (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312, 637641.
  • Brami-Cherrier K., Valjent E., Garcia M., Pages C., Hipskind R. A. and Caboche J. (2002) Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J. Neurosci. 22, 89118921.
  • Brunet A., Bonni A., Zigmond M. J. et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857868.
  • Brunet A., Datta S. R. and Greenberg M. E. (2001) Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 11, 297305.
  • Cardone M. H., Roy N., Stennicke H. R., Salvesen G. S., Franke T. F., Stanbridge E., Frisch S. and Reed J. C. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 13181321.
  • Chan T. O., Rittenhouse S. E. and Tsichlis P. N. (1999) AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu. Rev. Biochem. 68, 9651014.
  • Chen J. P., Paredes W., Li J., Smith D., Lowinson J. and Gardner E. L. (1990) Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl.) 102, 156162.
  • Childers S. R. and Deadwyler S. A. (1996) Role of cyclic AMP in the actions of cannabinoid receptors. Biochem. Pharmacol. 52, 819827.
  • Cross D. A., Alessi D. R., Cohen P., Andjelkovich M. and Hemmings B. A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785789.
  • Deadwyler S. A., Hampson R. E., Mu J., Whyte A. and Childers S. (1995) Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 273, 734743.
  • Derkinderen P., Toutant M., Burgaya F., Le Bert M., Siciliano J. C., De Franciscis V., Gelman M. and Girault J. A. (1996) Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 273, 17191722.
  • Derkinderen P., Ledent C., Parmentier M. and Girault J. A. (2001) Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J. Neurochem. 77, 957960.
  • Derkinderen P., Valjent E., Toutant M., Corvol J. C., Enslen H., Ledent C., Trzaskos J., Caboche J. and Girault J. A. (2003) Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. 23, 23712382.
  • Downward J. (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10, 262267.
  • Fiore R. S., Bayer V. E., Pelech S. L., Posada J., Cooper J. A. and Baraban J. M. (1993) p42 mitogen-activated protein kinase in brain: prominent localization in neuronal cell bodies and dendrites. Neuroscience 55, 463472.
  • Franklin K. B. J. and Paxinos G. (1997) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
  • Galve-Roperh I., Rueda D., Gomez del Pulgar T., Velasco G. and Guzman M. (2002) Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol. Pharmacol. 62, 13851392.
  • Gomez del Pulgar T., Velasco G. and Guzman M. (2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. 347, 369373.
  • Gomez Del Pulgar T., De Ceballos M. L., Guzman M. and Velasco G. (2002) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 277, 3652736533.
  • Gould T. D. and Manji H. K. (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 12231237.
  • Grimes C. A. and Jope R. S. (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J. Neurochem. 78, 12191232.
  • Guzman M. (2005) Effects on cell viability. Handb Exp Pharmacol. 168, 627642.
  • Howlett A. C. (1998) The CB1 cannabinoid receptor in the brain. Neurobiol. Dis. 5, 405416.
  • Howlett A. C. and Fleming R. M. (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26, 532538.
  • Hutcheson D. M., Tzavara E. T., Smadja C., Valjent E., Roques B. P., Hanoune J. and Maldonado R. (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br. J. Pharmacol. 125, 15671577.
  • Jope R. S. and Johnson G. V. (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29, 95102.
  • King T. D., Bijur G. N. and Jope R. S. (2001) Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 919, 106114.
  • Klein P. S. and Melton D. A. (1996) A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. USA 93, 84558459.
  • Mackie K. and Hille B. (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89, 38253829.
  • Malone D. T. and Taylor D. A. (1999) Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br. J. Pharmacol. 128, 2126.
  • Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C. and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561564.
  • Meijer L., Flajolet M. and Greengard P. (2004) Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 25, 471480.
  • Molina-Holgado E., Vela J. M., Arevalo-Martin A., Almazan G., Molina-Holgado F., Borrell J. and Guaza C. (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 22, 97429753.
  • Molina-Holgado F., Pinteaux E., Heenan L., Moore J. D., Rothwell N. J. and Gibson R. M. (2005) Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol. Cell. Neurosci. 28, 189194.
  • Munro S., Thomas K. L. and Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 6165.
  • Pap M. and Cooper G. M. (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 273, 1992919932.
  • Rubino T., Forlani G., Vigano D., Zippel R. and Parolaro D. (2004) Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol. Cell. Neurosci. 25, 355362.
  • Rueda D., Galve-Roperh I., Haro A. and Guzman M. (2000) The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. 58, 814820.
  • Sanchez M. G., Ruiz-Llorente L., Sanchez A. M. and Diaz-Laviada I. (2003) Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell. Signal. 15, 851859.
  • Sarne Y. and Mechoulam R. (2005) Cannabinoids: between neuroprotection and neurotoxicity. Curr. Drug Targets CNS Neurol. Disord. 4, 677684.
  • Scheid M. P., Marignani P. A. and Woodgett J. R. (2002) Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol. Cell Biol. 22, 62476260.
  • Van Der Stelt M. and Di Marzo V. (2005) Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med. 7, 3750.
  • Tanda G., Pontieri F. E. and Di Chiara G. (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276, 20482050.
  • Valjent E., Corvol J. C., Pages C., Besson M. J., Maldonado R. and Caboche J. (2000) Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J. Neurosci. 20, 87018709.
  • Valjent E., Pages C., Rogard M., Besson M. J., Maldonado R. and Caboche J. (2001) Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur. J. Neurosci. 14, 342352.
  • Valjent E., Pages C., Herve D., Girault J. A. and Caboche J. (2004) Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur. J. Neurosci. 19, 18261836.
  • Valverde O., Maldonado R., Valjent E., Zimmer A. M. and Zimmer A. (2000) Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J. Neurosci. 20, 92849289.
  • Wartmann M., Campbell D., Subramanian A., Burstein S. H. and Davis R. J. (1995) The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett. 359, 133136.
  • Watcharasit P., Bijur G. N., Zmijewski J. W., Song L., Zmijewska A., Chen X., Johnson G. V. and Jope R. S. (2002) Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc. Natl Acad. Sci. USA 99, 79517955.